Peptide news
Curated weekly from FDA notices, manufacturer press releases, peer-reviewed studies, and trusted outlets. Direct source links on every item. Practical takeaways for users, not academic abstracts.
- Regulatorylilly.gcs-web.com
Lilly to present new data on Foundayo, retatrutide, and eloraTZP at EASD 2026, as it strives to change the course of cardiometabolic health
Lilly reports weight loss and A1C improvements with investigational retatrutide, while Foundayo results suggest possible cardiovascular benefits. It will also present Phase 2 data for eloraTZP, which combines eloralintide with tirzepatide. If you’re following these treatments, watch for the full EASD results from September 28 to October 2 to assess benefit sizes and side effects.
Read source → - Regulatorynews.google.com
Use of untested 'Wolverine' peptide backed by US Health Secretary Kennedy on the rise, study finds
A study reports growing use of the untested peptide nicknamed Wolverine, which US Health Secretary Kennedy has backed. If you're considering it, ask your clinician what human safety evidence exists before deciding to use it.
Read source → - Regulatorynews.google.com
Preserving Muscle During GLP-1 Weight Loss
Preserving muscle is part of managing your weight loss with a GLP-1 medication. Ask your clinician how to monitor your strength and muscle mass alongside the number on the scale.
Read source → - Regulatorynews.google.com
Scientists find Ozempic may slow aging itself
Research highlighted in the title suggests Ozempic may slow aging, but you cannot tell from the headline whether this was demonstrated in people or how aging was measured. Before using this claim to guide your peptide choices, check the study population and what actually improved.
Read source → - Regulatorynews.google.com
Tirzepatide Beats Semaglutide for Weight Loss, but Loses on Safety
The headline reports greater weight loss with tirzepatide than semaglutide, but a less favorable safety profile without specifying the risks. If you're comparing these medications, ask your prescriber which safety findings matter for you before changing treatment.
Read source → - Trialslilly.gcs-web.com
New Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together showed improved and durable efficacy at one year in adults with psoriatic disease and obesity
Lilly reports that Zepbound (tirzepatide) plus Taltz (ixekizumab) maintained or further improved psoriasis and psoriatic arthritis outcomes at Week 52 compared with Week 36. The combination had outperformed Taltz alone at Week 36 in two open label Phase 3b trials, meaning participants and researchers knew which treatments were given. If you have psoriatic disease and obesity, ask your specialist whether tirzepatide could fit alongside your current treatment.
Read source → - Regulatorylilly.gcs-web.com
FDA approves Lilly's Mounjaro (tirzepatide) to reduce cardiovascular risk in adults with type 2 diabetes
Lilly reports that the FDA approved Mounjaro (tirzepatide) to reduce the risk of heart attack, stroke or cardiovascular death in adults with type 2 diabetes at high cardiovascular risk, adding to its existing blood sugar indication. If you have type 2 diabetes, ask your prescriber whether your cardiovascular risk makes this new approved use relevant to your treatment.
Read source → - Regulatorylilly.gcs-web.com
La FDA aprueba Mounjaro (tirzepatida) de Lilly para reducir el riesgo cardiovascular en adultos con diabetes tipo 2
Lilly reports that the FDA approved Mounjaro (tirzepatide) to reduce the risk of heart attack, stroke, or cardiovascular death in adults with type 2 diabetes at high cardiovascular risk. If you have type 2 diabetes, ask your prescriber whether your cardiovascular risk makes this new indication relevant to your treatment.
Read source → - Regulatorynews.google.com
Weight Down, Steps Down: The GLP-1 Catch
The headline suggests that weight loss during GLP-1 treatment may coincide with fewer daily steps. If you use a GLP-1, track your steps alongside your weight so you can spot whether you’re moving less as you lose weight.
Read source → - Costlilly.gcs-web.com
Zepbound linked to lower healthcare costs in adults over age 55 with obesity according to a real-world study
A Lilly study of adults over 55 with overweight or obesity linked sustained Zepbound use to fewer hospital admissions and emergency visits compared with similar untreated adults. Monthly healthcare costs were up to 15% lower at six months, or up to $181 per patient, but those estimates excluded Zepbound’s cost. If you’re weighing affordability, check your prescription coverage and out of pocket price before assuming these findings mean a lower total bill.
Read source → - Regulatorynews.google.com
GLP-1s and Birth Control; Retatrutide Lawsuits; Air Pollution and Menopause
This roundup covers birth control considerations with GLP-1s and lawsuits involving retatrutide. If you use a GLP-1 and birth control, ask your pharmacist to check the contraceptive guidance for your specific medication.
Read source → - Safetynews.google.com
Ozempic Teeth, Muscle Loss: Some of the Buzziest GLP-1 Side Effects
Dental problems dubbed Ozempic teeth and muscle loss are getting attention as possible GLP-1 side effects, but the title alone cannot establish their cause or frequency. If you use a GLP-1, flag new dental symptoms or declining strength to your prescriber.
Read source →
Pepdex aggregates research news from primary sources only, FDA Federal Register notices, manufacturer investor releases, peer-reviewed studies on PubMed / NEJM / Lancet, and trusted outlets (BioPharma Dive, STAT, AJMC, university research pages). We summarize in plain English; you click the source link to verify. No vendor sponsorship.